Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
On December 18, 2024, the Food and Drug Administration approved ensartinib for adult patients with locally advanced or metastatic Non-Small-Cell Lung Carcinoma (NSCLC) (ALK m) who have not previously received an ALK-inhibitor.
Efficacy was evaluated in NCT02767804 - eXalt3 - 1L - Ensartinib vs Crizotinib & Non-Small-Cell Lung Carcinoma (NSCLC) (ALK m), an open-label, randomized, active-controlled, multicenter trial in 290 patients with locally advanced or metastatic Non-Small-Cell Lung Carcinoma (NSCLC) (ALK m), who had not previously received an ALK-targeted therapy. Patients were randomized 1:1…